# Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Canonical URL: https://biopharmsignal.com/news/STTK/shattuck-labs-announces-exercise-of-outstanding-common-stock-warrants-and-provid-5897ec16
Ticker: STTK
Company: Shattuck Labs
Source: Shattuck Labs
Published: 2026-06-09 12:00 EST
## Summary

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling approximately 50.6 million common stock warrants to date, representing approximately 96% of the warrants issued in the Company's August 4, 2025 private placement. The exercise of these warrants is expected to result in aggregate gross proceeds of approximately $54.9 million. As of March 31, 2026, the Company had received aggregate gross proceeds of approximately $5.6 million pursuant to the exercise of 5,147,773 warrants. The Company expects to receive additional aggregate gross proceeds totaling approximately $49.3 million from the exercise of 45,438,709 common stock warrants since March 31, 2026. Together with existing cash and cash equivalents and short term investments of approximately $90.4 million as of March 31, 2026, Shattuck expects to be able to fund operations into 2029. This cash runway guidance is based on the Company’s current operational plans and excludes any additional capital that may be received (other than from the exercise of these common stock warrants), proceeds from business development transactions, and/or additional costs associated with clinical development activities that may be undertaken.

## Article Body
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling approximately 50.6 million common stock warrants to date, representing approximately 96% of the warrants issued in the Company's August 4, 2025 private placement. The exercise of these warrants is expected to result in aggregate gross proceeds of approximately $54.9 million. As of March 31, 2026, the Company had received aggregate gross proceeds of approximately $5.6 million pursuant to the exercise of 5,147,773 warrants. The Company expects to receive additional aggregate gross proceeds totaling approximately $49.3 million from the exercise of 45,438,709 common stock warrants since March 31, 2026. Together with existing cash and cash equivalents and short term investments of approximately $90.4 million as of March 31, 2026, Shattuck expects to be able to fund operations into 2029. This cash runway guidance is based on the Company’s current operational plans and excludes any additional capital that may be received (other than from the exercise of these common stock warrants), proceeds from business development transactions, and/or additional costs associated with clinical development activities that may be undertaken.
## Recent Company News
- 2026-06-10 04:21 EST — [Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-pricing-of-75-million-public-offering-1147ed04) — Source: Shattuck Labs
- 2026-06-09 20:18 EST — [Shattuck Labs, Inc. Announces Proposed Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-proposed-public-offering-81c3c0e1) — Source: Shattuck Labs
- 2026-06-09 12:00 EST — [Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-exercise-of-outstanding-common-stock-warrants-and-provid-5897ec16) — Source: Shattuck Labs
- 2026-06-08 10:00 EST — [Shattuck Labs Announces Phase 1 Results for SL-325](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-phase-1-results-for-sl-325-e7f7caf7) — Source: Shattuck Labs
- 2026-06-05 20:05 EST — [Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8](https://biopharmsignal.com/news/STTK/shattuck-labs-to-host-investor-call-and-webcast-on-phase-1-clinical-data-of-sl-3-d25fd1ba) — Source: Shattuck Labs
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)